Feed Category: Women's Health Index

SYDNEY, AUSTRALIA, Jan. 31, 2025 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3…

The trial evaluates the GLSI-100 for preventing breast cancer recurrences. Credit: YAKOBCHUK VIACHESLAV/Shutterstock. The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’…

Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women’s Health Inc. (“Aspira” or the “Company”)…

Jack Smith’s final report on election interference case against Trump releasedSpecial counsel Jack Smith’s final report into Donald Trump’s alleged efforts to subvert the 2020…

FSAD is clinically analogous to erectile dysfunction in men.To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to…

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to…

Sabrina Johnson; President, Chief Executive Officer, Secretary, Director; Dare Bioscience Inc Douglas Tsao; Analyst; H.C. Wainwright & Co LLC Welcome to the conference call hosted…

Carl Spana; President, Chief Executive Officer, Director; Palatin Technologies Inc Steve Wills; CFO, COO, Executive VP, Treasurer & Secretary; Palatin Technologies Inc Joseph Pantginis; Analyst;…

Carl Spana; President, Chief Executive Officer, Director; Palatin Technologies Inc Steve Wills; CFO, COO, Executive VP, Treasurer & Secretary; Palatin Technologies Inc Joseph Pantginis; Analyst;…

Release Date: November 14, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Dare Bioscience Inc (NASDAQ:DARE)…

Release Date: November 14, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Dare Bioscience Inc (NASDAQ:DARE)…

Revenue: No product sales recorded for Q1 FY2025 due to the sale of Vyleesi rights; previous year’s Q1 net product revenue was $2.1 million. Operating…